AIRLINK 194.83 Decreased By ▼ -3.14 (-1.59%)
BOP 9.81 Decreased By ▼ -0.23 (-2.29%)
CNERGY 7.36 Increased By ▲ 0.07 (0.96%)
FCCL 38.58 Increased By ▲ 2.58 (7.17%)
FFL 16.45 Decreased By ▼ -0.46 (-2.72%)
FLYNG 27.54 Increased By ▲ 2.50 (9.98%)
HUBC 131.75 Decreased By ▼ -2.28 (-1.7%)
HUMNL 13.86 Decreased By ▼ -0.28 (-1.98%)
KEL 4.66 Decreased By ▼ -0.12 (-2.51%)
KOSM 6.66 Decreased By ▼ -0.28 (-4.03%)
MLCF 45.39 Increased By ▲ 0.41 (0.91%)
OGDC 213.99 Decreased By ▼ -4.24 (-1.94%)
PACE 6.86 Decreased By ▼ -0.08 (-1.15%)
PAEL 40.06 Decreased By ▼ -1.36 (-3.28%)
PIAHCLA 16.79 Decreased By ▼ -0.07 (-0.42%)
PIBTL 8.32 Decreased By ▼ -0.14 (-1.65%)
POWER 9.43 Increased By ▲ 0.04 (0.43%)
PPL 182.19 Decreased By ▼ -3.74 (-2.01%)
PRL 41.83 Increased By ▲ 0.56 (1.36%)
PTC 24.56 Decreased By ▼ -0.21 (-0.85%)
SEARL 102.53 Decreased By ▼ -2.12 (-2.03%)
SILK 1.00 Decreased By ▼ -0.01 (-0.99%)
SSGC 39.44 Decreased By ▼ -1.47 (-3.59%)
SYM 17.33 Decreased By ▼ -0.72 (-3.99%)
TELE 8.76 Decreased By ▼ -0.15 (-1.68%)
TPLP 12.75 Decreased By ▼ -0.09 (-0.7%)
TRG 65.40 Decreased By ▼ -1.20 (-1.8%)
WAVESAPP 11.11 Decreased By ▼ -0.19 (-1.68%)
WTL 1.70 Decreased By ▼ -0.08 (-4.49%)
YOUW 3.94 Decreased By ▼ -0.06 (-1.5%)
BR100 11,988 Decreased By -121.3 (-1%)
BR30 36,198 Decreased By -400.2 (-1.09%)
KSE100 113,443 Decreased By -1598.8 (-1.39%)
KSE30 35,635 Decreased By -564.3 (-1.56%)
Business & Finance

Russia's Sputnik V developers to sue Brazilian regulator for 'false information' about their vaccine

  • The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.
  • A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.
Published April 29, 2021

MOSCOW: Russian developers of the Sputnik V vaccine against COVID-19 said on Thursday that they were suing Brazilian regulator Anvisa for defamation, accusing it of having knowingly spread false information without testing their product.

The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.

A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.

Sputnik V's official Twitter account on Thursday cited a Brazilian media story citing the same expert as saying that no tests had been carried out to test the Brazilian theory.

"Following the admission of Brazilian regulator Anvisa that it did not test Sputnik V vaccine, Sputnik V is undertaking a legal defamation proceeding in Brazil against Anvisa for knowingly spreading false and inaccurate information," it said.

"Anvisa made incorrect and misleading statements without having tested the actual Sputnik V vaccine."

Comments

Comments are closed.